R&D valuation model audit and upgrade

One of the 10 largest pharmaceutical companies in the world had internally developed a comprehensive R&D valuation (template) model that was used to evaluate all (100+) pipeline drugs. The results of the model were used to support go-no-go decisions, R&D portfolio prioritizations and to support M&A transactions. However, the model had never been independently audited, didn’t have comprehensive documentation and training materials, and users had requested a variety of enhancements. EpiX completed a thorough audit of the model and made a number of critical enhancements that greatly increased the model’s speed and accuracy.

Learn more about this project    Back to all case studies


We believe in seeing to believe.

View our client success stories to read about our projects.


Once in a while, we ask our clients, course participants and co-investigators to provide us with testimonials of their experience working with us. Read what they're saying about us.